These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1311 related articles for article (PubMed ID: 16544145)
21. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance. Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444 [TBL] [Abstract][Full Text] [Related]
22. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo. Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326 [TBL] [Abstract][Full Text] [Related]
23. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts. Ramachandran C; Wellham LL Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558 [TBL] [Abstract][Full Text] [Related]
24. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice. Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185 [TBL] [Abstract][Full Text] [Related]
25. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi. Xiao H; Wu Z; Shen H; Luo AL; Yang YF; Li XB; Zhu DY Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):342-8. PubMed ID: 18834355 [TBL] [Abstract][Full Text] [Related]
26. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Wang TX; Yang XH Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331 [TBL] [Abstract][Full Text] [Related]
27. The anticancer activity of the transcription inhibitor terameprocol (meso-tetra-O-methyl nordihydroguaiaretic acid) formulated for systemic administration. Lopez RA; Goodman AB; Rhodes M; Blomberg JA; Heller J Anticancer Drugs; 2007 Sep; 18(8):933-9. PubMed ID: 17667599 [TBL] [Abstract][Full Text] [Related]
28. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. Chen G; Waxman DJ J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498 [TBL] [Abstract][Full Text] [Related]
29. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1. Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441 [TBL] [Abstract][Full Text] [Related]
30. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells. Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039 [TBL] [Abstract][Full Text] [Related]
31. Selection of antisense oligonucleotides for reversal of multidrug resistance in breast carcinoma cells. Gao P; Zhou GY; Lei DP; Zhang XF; Li L; Xu JW; Lin XY Cytotherapy; 2007; 9(8):795-801. PubMed ID: 17917879 [TBL] [Abstract][Full Text] [Related]
32. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin. Qi X; Chang Z; Song J; Gao G; Shen Z Anticancer Drugs; 2011 Jul; 22(6):556-62. PubMed ID: 21637162 [TBL] [Abstract][Full Text] [Related]
33. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells. Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366 [TBL] [Abstract][Full Text] [Related]
34. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Xu D; Lu Q; Hu X Cancer Lett; 2006 Nov; 243(2):274-80. PubMed ID: 16406853 [TBL] [Abstract][Full Text] [Related]
35. Reversal of multidrug resistance by small interfering RNA (siRNA) in doxorubicin-resistant MCF-7 breast cancer cells. Dönmez Y; Gündüz U Biomed Pharmacother; 2011 Mar; 65(2):85-9. PubMed ID: 21237614 [TBL] [Abstract][Full Text] [Related]
36. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo. Ren Y; Wang Y; Zhang Y; Wei D Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970 [TBL] [Abstract][Full Text] [Related]
37. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype. Mi Q; Cui B; Silva GL; Lantvit D; Lim E; Chai H; You M; Hollingshead MG; Mayo JG; Kinghorn AD; Pezzuto JM Cancer Res; 2001 May; 61(10):4030-7. PubMed ID: 11358822 [TBL] [Abstract][Full Text] [Related]
38. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines. Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251 [TBL] [Abstract][Full Text] [Related]
39. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Chavanpatil MD; Patil Y; Panyam J Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148 [TBL] [Abstract][Full Text] [Related]
40. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]